Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2): a Prospective, Randomized, Open Label, Blinded Endpoint, and Multi-center Study

NCT06010628 is registered in ClinicalTrials.gov with General Hospital of Shenyang Military Region as lead sponsor.

NCT NCT06010628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06010628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2): a Prospective, Randomized, Open Label, Blinded Endpoint, and Multi-center Study
Lead sponsor
General Hospital of Shenyang Military Region
Phase
Phase 4
Overall status
Recruiting
Start date
February 1, 2024
Completion date
December 15, 2029
Enrollment
1,440 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stroke, ischemic